Evidence map›Paper›PMID 26172479›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

Piyanuch Kongtim, Dean A Lee, Laurence J N Cooper, Partow Kebriaei, Richard E Champlin, Stefan O Ciurea

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 31 citations in OpenAlex.

  1. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Cells to prevent/treat relapse following allogeneic stem cell transplantation.Hematology. American Society of Hematology. Education Program · 2017
    Review
  9. Natural Killer Cells for Therapy of Leukemia.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Piyanuch KongtimDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas; Division of Hematology, Department of Internal Medicine, Faculty of Medicine Thammasat University, Thailand.
Dean A LeeDepartment of Pediatrics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Laurence J N CooperDepartment of Pediatrics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Stefan O CiureaDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: sciurea@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 1990 to 2014
$41.8M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Haploidentical transplantation can extend the opportunity for transplantation to almost all patients who lack an HLA-matched donor. Advances in the field of haploidentical transplantation have led to a marked decrease in treatment-related mortality, allowing investigators to focus on developing rationale pre- and peri-remission therapies aimed at preventing disease relapse after transplantation. Because of widespread availability, low treatment-related mortality, and cost, haploidentical donors may become the preferred "alternative" donors for allogeneic hematopoietic stem cell transplantation. One of the major advantages of using a related donor is the possibility of collecting or generating additional cellular products from the same immediately available donor, which will not be rejected. Infusion of these cells in the peri-transplantation period, derived from the same immune system, is opening the possibility of markedly enhancing the antitumor effects of the graft and hastening immunologic reconstitution after transplantation.

Indexed as

HaplotypesHistocompatibilityCyclophosphamideGenes, Transgenic, SuicideHematopoietic Stem Cell TransplantationHLA AntigensHumansImmunotherapy, AdoptiveKiller Cells, NaturalLiving DonorsLymphocyte DepletionPhotosensitizing AgentsReceptors, Antigen, T-CellRhodaminesT-LymphocytesTransplantation Immunology4,5-dibromorhodamine 123CD19-specific chimeric antigen receptorCyclophosphamideHLA AntigensPhotosensitizing AgentsReceptors, Antigen, T-CellRhodaminesAlpha-beta T cell depletionCellular therapyChimeric antigen receptor T cellsDonor lymphocyte infusionHaploidentical transplantationNatural killer cellsPost-transplantation cyclophosphamide

Identifiers

PMID26172479
PMCPMC4825320
OpenAlexW1776408811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.